Table 4: Lines of treatment and outcomes.

Subtype

Stage

1st recorded line of treatment

Outcome if available

2nd recorded line of treatment

Outcome

3rd recorded line of treatment

Outcome

Sézary syndrome

4

Methotrexate

ongoing

PTCL-NOS

3

CHOEP-21

ongoing

PTCL-NOS

3

CHOP-21

death

Enteropathy-associated TCL

4

CHOEP-21

PD

DHAP

PD/death

Anaplastic large cell lymphoma (ALK+/-)

4

CHOEP-21

ongoing\death

Angioimmunoblastic TCL

4

COP

missing

CHOEP-21

ongoing

CHOP14

PR

Adult T-cellleukemia/lymphoma

4

CHOP-21

SD

Adult T-cellleukemia/lymphoma

4

CHOP-21

ongoing

Primary cutaneous CD30- positive T-cell lymphoproliferative disorders

1

CHOP-21

ongoing\CR

NKTCL nasal Type

2

CHOEP-21

ongoing\death

NKTCL nasal Type

4

CHOP-21

death

Enteropathy-associated TCL

4

CHOP-21

ongoing\death

PTCL-NOS

3

Bendamustine

PD

ESHAP

SD\death

PTCL-NOS

3

CHOP-21

ongoing\death

PTCL-NOS

4

CHOP-21

death

PTCL-NOS

4

CHOEP-21

death

Anaplastic large cell lymphoma (ALK+/-)

2

CHOP-21

ongoing\death

Anaplastic large cell lymphoma (ALK+/-)

4

VCAP

ongoing\death

Adult T-cell leukemia/lymphoma

4

CHOEP-21

SD\death

Adult T-cell leukemia/lymphoma

4

CHOP-21

PD

GEMOX

PD\death

Adult T-cellleukemia/lymphoma

4

lost to follow up

T-cell large granular lymphocytic leukemia

4

death

Not available-stage 1

1

CHOP-21

Ongoing

ESHAP

PD\death

Transformed mycosis fungoides

4

COP

ongoing

CHOEP-21

SD

COEP and methotrexate

SD\death

PTCL-NOS

4

COP

PD

COEP

ongoing

Primary cutaneous CD30- positive T-cell lymphoproliferative disorders

1

CHOP-21

SD then PR

Angioimmunoblastic TCL

4

cyclophosphamide

Cyclophosphamide/Etoposide/Prednisone

PD

CVP

ongoing

Adult T-cell leukemia/lymphoma

4

CHOP-21

PR then PD

GEMOX

ongoing

NKTCL Nasal Type

2

CHOP-21

death

Enteropathy-associated TCL

2

CHOEP-21

SD\death

Anaplastic large cell lymphoma (ALK+/-)

4

CHOP-21

CR

CHOEP-21

PR

Angioimmunoblastic TCL

3

CHOP-21

Angioimmunoblastic TCL

4

COP

CHOEP-21

death

Lymphoblastic T lymphoma

4

Mini CHOP

PD

Methotrexate + asparaginase

CR\death

  

Angioimmunoblastic TCL

3

CHOP-21

PR then PD then CR

Adult T-cell leukemia/lymphoma

4

CHOEP-21

PR\death

Mycosis fungoides

4

CHOP-21\CHOEP-21

CR\PD

CHOEP-21

SD

Sézary syndrome*

4

CHOEP-21

PR

DHAP

PR\death

Primary cutaneous CD30- positive T-cell lymphoproliferative disorders

3

CHOEP-21

SD

Gemcitabine

SD

Adult T-cell leukemia/lymphoma

4

Adult T-cell leukemia/lymphoma

4

COP/CHOP-21

SD\death

PTCL-NOS

3

CHOP-21

SD\PD

CHOEP-21

SD

Gemcitabine

SD\death

PTCL-NOS

4

CHOP-21

CR

Anaplastic large cell lymphoma (ALK+/-)

2

CHOEP-21

CR

ESHAP

Anaplastic large cell lymphoma (ALK+/-)

3

CHOEP\CHOEP-21

SD\CR

COEP

CR

Anaplastic large cell lymphoma (ALK+/-)

3

COP

DHAP

PD

COEP

Primary cutaneous CD30- positive T-cell lymphoproliferative disorders

CHOP-21

SD

L Asparaginase/ Methotrexate

SD

GDP

NKTCL Nasal Type

1

CHOP-21

CR

Radiotherapy

PR

Anaplastic large cell lymphoma (ALK+/-)

3

CHOEP-21

SD\PD

ICE

Vélbé Dexamethasone /Interventional treatment Gemcitabine Dexamethasone/Gemcitabine/Etoposide

PD\death

PTCL-NOS

4

CHOP-21

SD\PD

GEMOX

PD\death

PTCL-NOS

3

CHOEP-21

CR

PTCL-NOS

4

HyperCVAD alternating with high-dose methotrexate and cytarabine

PD\CR

D-BEGEV\linker

CR

T-cell prolymphocytic leukemia stage 4

4

Linker

CR

Sézary syndrome stage 4

4

CHOP-21

SD

methotrexate

SD

NKTCL Nasal Type

2

CHOP-21

CR\PD

GEMOX

CR

radio therapy

CR

T-cell large granular lymphocytic leukemia

4

CHOP-21

SD

Gemcitabine

SD

Fludarabine

SD

Lymphoblastic T lymphoma

2

Linker

CR

Adult T-cell leukemia/lymphoma

4

CHOP-21\CHOEP-21

Methotrexate asparaginase\Linker\methotrexate high dose

CR

Anaplastic large cell lymphoma (ALK+/-)

4

Mini chop

CR

Anaplastic large cell lymphoma (ALK+/-)

4

CHOP-21

CR\relapse

Linker

*The baseline treatment given to this patient is not expected to be the first line of treatment since the time between the date of diagnosis and date of the first recorded line of treatment is 158 days.

BEGEV: Bendamustine, Gemcitabine, Vinorelbine; CHOP: Cyclophosphamide, Hydroxyrubicin, Vincristine, Prednisone; CHOEP: Cyclophosphamide, Hydroxyldaunorubicin (Doxorubicin), Vincristine, Etoposide, Prednisone; COEP: Cyclophosphamide, Vincristine, Etoposide, Prednisone; COP: Cyclophosphamide, Vincristine, Prednisone; CVAD: Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone; CVP: Cyclophosphamide, Vincristine, Prednisone; DHAP: Dexamethasone, Ara-C, Cytarabine, Cisplatin; ESHAP: Etoposide, Methylprednisolone, Cytarabine, Cisplatin; GDP: Gemcitabine, Dexamethasone, Cisplatin; GEMOX: Gemcitabine, Oxaliplatin; ICE: Ifosfamide, Carboplatin, Etoposide; Linker: (1) Daunorubicin, Vincristine, Prednisone, Asparaginase, or (2) Daunorubicin, Vincristine, Asparaginase, Methotrexate, Cytarabine, Cyclophosphamide, Purinethol, vp16; VCAP: Vincristine, Cyclophosphamide, Doxorubicin, Prednisolone.

CR: Complete Remission/Complete Response; PD: Progressive Disease; PR: Partial Response/Partial Remission; SD: Stable Disease